Altria Group, Inc. (MO) Financial Statements

Altria Group, Inc.

MO · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$23.28B	$24.02B	$24.48B	$25.10B	$26.01B	$26.15B	$25.11B	$25.36B
Cost of Revenue	$5.60B	$6.08B	$6.22B	$6.44B	$7.12B	$7.82B	$7.08B	$7.37B
Gross Profit	$14.54B	$14.37B	$14.28B	$14.25B	$13.99B	$13.02B	$12.71B	$12.25B
Research & Development	$195.00M	$208.00M	$220.00M	$162.00M	$145.00M	$131.00M	$168.00M	$252.00M
Operating Income	$9.90B	$11.24B	$11.55B	$11.92B	$11.56B	$10.87B	$10.33B	$9.12B
Interest Expense	—	—	$1.15B	$1.13B	$1.19B	$1.22B	$1.32B	$697.00M
Income Before Taxes	$9.39B	$13.66B	$10.93B	$7.39B	$3.82B	$6.89B	$766.00M	$9.34B
Provision for Income Taxes	$2.44B	$2.39B	$2.80B	$1.63B	$1.35B	$2.44B	$2.06B	$2.37B
Net Income	$6.95B	$11.26B	$8.13B	$5.76B	$2.48B	$4.47B	-$1.29B	$6.96B
Basic EPS	$4.12	$6.54	$4.57	$3.19	$1.34	$2.40	-$0.70	$3.69
Diluted EPS	$4.12	$6.54	$4.57	$3.19	$1.34	$2.40	-$0.70	$3.68
Basic Shares Outstanding	1.68B	1.72B	1.78B	1.80B	1.84B	1.86B	1.87B	1.89B
Diluted Shares Outstanding	1.68B	1.72B	1.78B	1.80B	1.84B	1.86B	1.87B	1.89B

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$5.68	$5.65	$5.71	5	↑1 ↓3
Dec 2027	$5.86	$5.77	$5.96	6	↑2 ↓2
Dec 2028	$6.02	$5.87	$6.12	3	↑1 ↓1
Dec 2029	$6.15	$6.03	$6.28	2	↑1 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: MO
Type: Stock
Sector: Health Care
Industry: Medicinal Chemicals and Botanical Products
Country: North America
Exchange: NYSE

Altria Group, Inc. is a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. We are Moving Beyond Smoking®, by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers and exploring new growth opportunities - beyond the United States and beyond nicotine (Vision). To achieve our Vision, we will pursue initiatives designed to promote the long-term welfare of our company, our stakeholders, society at large and the environment.

Key Issues

Bullish view

Higher pricing has supported smokeable-products revenue and profit despite lower cigarette shipments, demonstrating continued pricing power and resilient demand.

Bearish view

Declining cigarette volumes and a growing shift toward discount brands can eventually overwhelm pricing, as reflected in the second-quarter earnings miss.

Analyst Consensus

See all

Hold

13 analysts

$68

Current

—

Low

$71

Average

—

High

Average target implies +3.50% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Vertex Pharmaceuticals IncorporatedVRTX · NASDAQ-GS$482.57